Mazdutide Guide
GCG/GLP-1 Dual Agonist Weight Loss 2026
Complete guide to Mazdutide (IBI362) — Innovent
What Is Mazdutide Guide?
Mazdutide (development code IBI362) is a long-acting, once-weekly glucagon-like peptide-1 (GLP-1) and glucagon (GCG) co-agonist developed by Innovent Biologics. The dual mechanism targets two complementary metabolic pathways: GLP-1 agonism reduces appetite and food intake, while GCG agonism dramatically increases energy expenditure and drives hepatic fat oxidation. This combination addresses obesity from both sides of the energy equation simultaneously — reducing calorie intake while increasing calorie burning. The GLORY Phase 3 trials in China were completed in 2024, establishing Mazdutide as one of the most clinically advanced GCG/GLP-1 candidates globally.
Key Biohacking Mechanics
Activates hypothalamic appetite centers
Slows gastric emptying → prolonged satiety
Enhances glucose-dependent insulin release
Reduces food cravings and total caloric intake
Increases basal metabolic rate (energy expenditure)
Promotes hepatic fat oxidation (reduces liver fat)
Drives lipolysis in adipose tissue
Unique to this drug class vs GLP-1/GIP
14.5% avg body weight loss at 3mg dose
48-week trial in adults with obesity
Significant liver fat reduction (MASLD benefit)
Improved blood pressure and lipids
86% liver fat reduction in NASH/MASLD subgroups
Systolic BP reduced by 6-8 mmHg
Significant triglyceride reduction
Waist circumference reduction >12cm
Expected Dosing Schedule
Starter dose to minimize GI side effects
First therapeutic escalation step
Mid-range dose showing good efficacy
Maximum dose — achieved 14.5% weight loss in GLORY
Note: Final approved dosing may vary. Follow your prescriber's guidance. Use Shotlee to log each weekly dose and monitor your progress.
Side Effects
Common Side Effects
Nausea (most common, dose-dependent). Vomiting. Diarrhea. Constipation. Injection site reactions
Glucagon-Related Notes
Transient blood glucose elevation possible. Managed by GLP-1 component counterbalance. GI adverse events similar to GLP-1 monotherapy. No unexpected cardiac signals in trials. Low discontinuation rate
Development Timeline
2022-2023:
Phase 2 trials established safety and efficacy dose range
2024:
Phase 3 GLORY trials completed — 14.5% weight loss at 3mg
2025:
NMPA (China) regulatory submission for obesity indication
2025-2026:
Potential China approval and global partnership/licensing discussions
Vital Protocol FAQs
How does Mazdutide\'s GCG agonism differ from tirzepatide\'s GIP agonism?
Tirzepatide adds GIP receptor activation which enhances GLP-1 effects and improves insulin sensitivity. Mazdutide adds glucagon receptor activation which drives energy expenditure and liver fat oxidat
Is Mazdutide available outside China?
Currently Mazdutide is only available in China after completing GLORY trials there. International rights have not been finalized. A global partnership or licensing deal would be needed for FDA/EMA fil
Can I track a Mazdutide protocol with Shotlee?
Yes — Shotlee supports custom weekly injectable tracking. Log your Mazdutide doses, track your weight loss progress, and monitor side effects weekly with the free Shotlee app.
Guide FAQs
Complete guide to Mazdutide (IBI362) — Innovent
Yes. Shotlee supports tracking Mazdutide doses, side effects, and health metrics. It is free to use.
References
Track Your Mazdutide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free